Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Mirati Therapeutics Inc. has received FDA clearance of its IND application for MRTX-1133, a potent, oral small-molecule inhibitor of the KRAS G12D driver mutation.
Coherent Biopharma Ltd. has divulged peptide-drug conjugates comprising cytotoxic drug covalently linked to folate receptor α (FOLR1; FR- α)-targeting moiety through linker reported to be useful for the treatment of cancer and metabolic, immunological and neurological disorders.
Pancreatic cancer is an exceptionally lethal cancer that is notoriously treatment resistant, in part due to poor vascularization in the tumor microenvironment. Investigators working at the Moores Cancer Center at the University of California, San Diego (UCSD), reported in the Jan. 16, 2023, issue of Nature Cell Biology on the discovery of a pathway that was initiated by isolation stresses (e.g., hypoxia, nutrient deprivation, and/or lack of extracellular matrix, ECM) leading to this cellular transformation in the tumor-initiating pancreatic cancer cell.
Beijing Innocare Pharma Tech Co. Ltd. has divulged heterocyclic compounds acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for treatment of cancer.
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions.
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Tumors have a lower interstitial pH compared to healthy tissues, with tumor acidity having emerged as a driver of tumor progression as it can lead to tumor immune evasion. Solute carrier family 4 member 4 (SLC4A4), which encodes a sodium bicarbonate cotransporter involved in pH regulation and homeostasis in normal tissue, was the focus of studies in pancreatic cancer resistance in in vivo preclinical models. Researchers tested the impact of Slc4a4 deletion in cancer cells on tumor growth, anticancer immunity and response to immunotherapy in murine models of pancreatic ductal adenocarcinoma (PDAC).
Bertis Co. Ltd.’s artificial intelligence (AI)-based diagnosis model is able to detect diseases, such as cancers, with more than 95% accuracy, according to preliminary testing results reported at the Human Proteome Organization 2022 meeting in Cancun, Mexico on Dec. 8.
